Moderna's Legal Gauntlet: Patent Wars, Investor Lawsuits, and a Reputation Under Siege

Moderna built its reputation — and its trillion-dollar-adjacent valuation at the height of the pandemic — on the promise that its mRNA platform was proprietary, defensible, and scientifically unassailable. Three years and several courtrooms later, that narrative is under sustained legal and financial pressure, with a stack of active lawsuits calling into question both the originality of its core technology and the honesty of its public statements to investors.

Patent Infringement: The Foundation Fight

The most structurally serious threat to Moderna isn't a single lawsuit — it's a pattern. In October 2024, Northwestern University filed suit alleging willful infringement of three patents covering the lipid nanoparticle (LNP) delivery technology that makes Moderna's Spikevax vaccine possible. According to Big Molecule Watch, the Northwestern complaint followed closely on the heels of a similar suit brought earlier in 2024 by GlaxoSmithKline, meaning Moderna is now defending its signature delivery mechanism against two separate, well-resourced plaintiffs simultaneously. LNP technology isn't a peripheral detail of Moderna's vaccines — it's the delivery vehicle that makes mRNA therapeutics viable in the human body at all. When two institutions independently allege willful infringement on the same underlying science, it raises uncomfortable questions about whether Moderna's platform was ever as originally-developed as its marketing and IPO materials suggested.

This isn't Moderna's first rodeo on this front. Back in February 2022, Arbutus Biopharma Corporation and Genevant Sciences GmbH filed a patent infringement action against Moderna in the District of Delaware, again centered on delivery technology used in Moderna's products, according to court records via CourtListener. That case has ground through the federal docket for years — a slow-burn liability that rarely makes headlines on any given day but that plaintiffs' attorneys and competitors watch closely, and that materially affects how the market prices Moderna's long-term freedom to operate. Taken together, the GSK, Northwestern, and Arbutus/Genevant suits form a triangulated legal assault on the very IP moat Moderna investors were told protected its market position. For a biotech company, an unresolved patent-infringement cloud over your flagship delivery technology isn't just a legal cost center — it's an existential brand and valuation risk, the kind of slow-moving crisis that rarely gets the crisis-communications attention it deserves until a verdict or settlement forces the issue into headlines.

Securities Fraud: The RSV Vaccine Reckoning

While the patent fights concern Moderna's past, a separate legal front concerns whether the company was straight with investors about its future. A securities fraud class action detailed by Robbins LLP alleges Moderna misled shareholders about the efficacy and commercial prospects of mRESVIA (mRNA-1345), its RSV vaccine, positioned as a key pillar of the company's post-COVID revenue diversification story. When the alleged truth came out, Moderna's stock dropped roughly 11% in a single move — the kind of drop that turns disappointed retail investors and institutional funds alike into class-action plaintiffs. This is a textbook example of how unmanaged forward guidance and overly optimistic public statements can metastasize into full-blown securities litigation. Once a stock takes an 11% hit tied to specific alleged misstatements, the company isn't just fighting a legal claim — it's fighting a narrative that it can't be trusted to accurately represent its own pipeline, which bleeds into analyst coverage, retail sentiment, and even recruiting.

Why This Matters Beyond the Courtroom

None of these cases individually threatens to sink Moderna. But collectively, they paint a picture that's increasingly hard for the company's communications team to control: a business whose foundational technology is legally contested by multiple parties, and whose public statements about newer products have already been formally alleged to be misleading. That combination is corrosive precisely because it compounds. Reporters covering the RSV securities case reference the patent disputes for context. Analysts weighing in on the patent disputes cite the securities case as evidence of a pattern of overpromising. Search results and AI-generated summaries about

Sources

1. Big Molecule Watch — GlaxoSmithKline and Northwestern Sue Moderna for Patent Infringement in Trio of Lawsuits - Big Molecule Watch
2. Robbins LLP — Moderna, Inc. Class Action
3. CourtListener — Arbutus Biopharma Corporation v. Moderna, Inc., 1:22-cv-00252 – CourtListener.com

Disclaimer: The information presented in this article was published by third parties and is aggregated here for research and commentary purposes only. NegativePublicRelations.com does not claim these allegations as fact; all claims are attributed to their original publishers, linked above. Readers are encouraged to review the original sources. This post is not legal advice.